focus -WSS

focus

author：leisure time 2025-09-29 18:16:59 - browse：15

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

WSS

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Alabama hospital puts IVF treatments on hold

Results on Novartis prostate cancer therapy could expand its use

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

FDA clears Verve to begin U.S. study of gene

Readout LOUD podcast: Live from the 2023 STAT Summit

hotspot

focus

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

6 phony surgeries that take placebo to the extreme

Virginia high school admissions case could be legal follow

Results on Novartis prostate cancer therapy could expand its use

In Memoriam: Notable people who died in 2023

Medicare inequities exacerbate Puerto Rico’s health disparities

Continuity nursing helped my family in our darkest PICU moments

With competition flaring, obesity drug hits goal in liver disease study

Cancer drug shortages should be causing more outrage

Why a market frenzy over new weight loss drugs defies logic

hotspot

He's a Nobel laureate. Critics say he was misleading on Covid

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Why a market frenzy over new weight loss drugs defies logic

Obesity drugs seen as possible treatment for liver disease MASH

Obesity drugs seen as possible treatment for liver disease MASH

STAT Summit: How researchers deal with rejection

entertainment

entertainment

leisure time

entertainment